Myriad Genetics Partners with Pathomiq to Add AI Technology Platform to its Oncology Portfolio

Myriad Genetics, Inc., a leader in molecular diagnostic testing and precision medicine, and PATHOMIQ, Inc., a developer of artificial intelligence (AI)-enabled prognostic and predictive tests for advancing access to personalized medicine and empowering treatment decisions, announced that they have entered into a strategic collaboration for Myriad to exclusively license PATHOMIQ_PRAD, PATHOMIQ’s AI technology platform for prostate cancer, in the United States.

Machine learning and AI-enabled diagnostics are transforming the way clinicians approach cancer patient care. Adding PATHOMIQ_PRAD to Myriad’s Oncology Solutions allows Myriad to provide urologist and radiation oncologists with molecular and AI-powered testing solutions to inform decisions both before treatment at the time of biopsy for active surveillance and following surgery or radiation treatment. This complements Myriad’s existing offerings of combined germline and comprehensive tumor profiling as recommended by NCCN guidelines for prostate cancer care.

“Along with our Prolaris Prostate Cancer Prognostic Test, we are pleased to leverage PATHOMIQ’s prognostic and predictive capabilities across different phases of the patient journey in prostate cancer,” said George Daneker, Jr., MD, President and Chief Clinical Officer, Oncology, Myriad Genetics. “Having both genetic and morphologic insights at the time of biopsy combined with the enhanced ability to predict disease recurrence after initial therapy can lead to more informed treatment decisions and enhance the potential for better patient outcomes. This partnership is the latest step in the strategic expansion of Myriad’s oncology portfolio. Our molecular science expertise, combined with the latest in machine learning and AI, will uniquely position Myriad to deliver higher-quality insights for patients and clinicians in the fight against cancer.”

HR Technology Insights: Pharmacy Profiles Achieves NCQA Certification as a Credentials Verification Organization

PATHOMIQ’s AI-technology platform decodes hidden information from complex morphological structures across all landscapes of cancer pathology to quickly and efficiently deploy new use cases to predict patient outcome, treatment response, and genotype mutations. This image-based technology can deliver results in one to two days after receiving the digital images from the patient’s sample.

“I am excited to have co-developed, with the PATHOMIQ team, the PATHOMIQ-PRAD AI model for prostate cancer treatment response prediction and identification of high-risk prostate cancer patients who will experience early metastasis post Radical Prostatectomy,” said Ashutosh K. Tewari, Chairman, Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mt Sinai. “The AI model has achieved high prediction accuracy and outperformed some of the currently used markers in both Caucasian and African American patient cohorts for a much-improved patient outcome.”

In addition to expanding Myriad’s prostate cancer testing portfolio to include post-surgical treatment testing solutions, the collaboration with PATHOMIQ is also envisioned to accelerate the timelines for meeting Simon level 1 evidence for both Prolaris and PATHOMIQ_PRAD. While the current PATHOMIQ_PRAD model is specific for use in patients with prostate cancer after surgery, the underlying foundational model provides opportunities for applications in virtually all solid tumor cancers that are diagnosed through a biopsy with H&E staining.

HR Technology Insights: Miller Children’s Care Network: Revolutionizing Pediatric Health Care

“Our collaboration with Myriad, a leader in cancer diagnostic tests, will help to advance precision medicine and improve prostate cancer disease outcomes,” said Rajat Roy, CEO and co-founder of PATHOMIQ. “Our AI-powered model has been successfully validated across multiple medical institutions and pharmaceutical partners. Combining Myriad’s extensive clinical expertise and broad customer reach with PATHOMIQ’s AI technology platform will allow more personalized treatment options for clinicians and their patients.”

Paul J. Diaz, President and CEO of Myriad, adds “PATHOMIQ’s technology platform, together with Myriad’s infrastructure and commercial capabilities allows for an accelerated pace of innovation to bring advanced diagnostic products to market that are clinically validated with faster turnaround times and at a lower cost.”

HR Technology Insights: National Youth Heart Screening Day: 3,300 Young Hearts Tested for Hidden Risks

Source – GlobeNewswire

To share your insights, please write to us at news@intentamplify.com

Tags: cancer patient care, diagnostic testing, oncologists, precision medicine

HealthTech Media Room

HealthTech Media Room is a leading B2B media publication platform providing in-depth coverage of the rapidly evolving healthcare technology and academic research sectors. Specializing in key focus areas such as MedTech, Pharma, Digital Health, Health IT, and Biotech, HealthTech Media Room delivers the latest news, trends, and insights across the entire HealthTech landscape. From breakthrough medical devices and innovative pharmaceuticals to cutting-edge digital health solutions, the platform highlights key players, strategic partnerships, and transformative technologies shaping the future of healthcare. Serving as a trusted resource for industry professionals, thought leaders, and healthcare organizations, HealthTech Media Room is dedicated to driving conversations and knowledge sharing in the global HealthTech community.